Table 1.
Demographics table for the healthy control (N = 21), Alzheimer’s disease (AD; N = 18), dementia with Lewy bodies (DLB; N = 17) and Parkinson’s disease dementia (PDD; N = 17) groups that were used for our analysis. L-DOPA = levo-dopa, LED = L-DOPA equivalent dose, AChEIs = acetylcholinesterase inhibitors, MMSE = Mini mental state examination, CAF = Clinician’s assessment of fluctuations scale, UPDRS = Unified Parkinson’s disease rating scale, NPI = Neuropsychiatric inventory total score. Although it is not shown in the table, 1 PDD patient (5.9%) was on memantine.
| Controls (N = 21) | AD (N = 18) | DLB (N = 17) | PDD (N = 17) | |
|---|---|---|---|---|
| Age in yrs ± SD | 76.19 ± 5.32 | 76.06 ± 7.81 | 75.71 ± 5.34 | 75.44 ± 4.66 |
| Males (%) | 66.7% | 88.9% | 88.2% | 100% |
| L-DOPA | – | 0% | 52.9% | 100% |
| LED | – | 0% | 348.94 | 423.42 |
| AChEIs | – | 94.4% | 88.2% | 76.5% |
| Age at diagnosis (yrs ± SD) | – | 74.64 ± 7.63 | 73 ± 5.11 | 74.07 ± 6.29 |
| Diagnosis duration (yrs ± SD) | – | 1.5 ± 0.9 | 1.08 ± 0.70 | 0.94 ± 0.73 |
| MMSE | 29.19 ± 0.87 | 23.67 ± 1.68 | 25 ± 2.89 | 23.94 ± 2.59 |
| CAF | – | 0.47 ± 0.87 | 2.76 ± 3.78 | 6.59 ± 4.29 |
| NPI total | – | 7.29 ± 7.61 | 8 ± 5.27 | 20.35 ± 12.9 |
| UPDRS | 1.14 ± 1.42 | 1.67 ± 1.61 | 13.82 ± 5.32 | 27.06 ± 11.44 |